Theralizumab

Drug Profile

Theralizumab

Alternative Names: TAB-08; TABO8

Latest Information Update: 27 Feb 2017

Price : $50

At a glance

  • Originator TheraMAB
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus
  • Phase I/II Plaque psoriasis
  • Phase I Solid tumours
  • No development reported Chronic lymphocytic leukaemia; Rheumatoid arthritis

Most Recent Events

  • 08 Feb 2017 Phase-I clinical trials in Solid tumours (Metastatic disease, Inoperable/Unresectable, Late-stage disease) in Russia (IV) (NCT03006029)
  • 26 Dec 2016 TheraMAB plans a phase Ib trial for Solid tumours (Metastatic disease, Inoperable/Unresectable, Late-stage disease) in Russia (NCT03006029)
  • 01 Dec 2016 TheraMAB completes a phase I/II trial in Plaque psoriasis in Russia (NCT02796053)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top